MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders, made a noteworthy announcement today. They have successfully concluded the enrollment and dosing phase of Study MMED008, a Phase 2b researching the effectiveness of MM-120 (lysergide D-tartrate) in addressing Generalized Anxiety Disorder (GAD).
MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
— jungle.java (@junglejava1) September 12, 2023
The MindMed study is a comprehensive, multi-center, parallel, randomized, double-blind, placebo-controlled dose-optimization study. The trial successfully recruited 198 participants who were randomly assigned to receive a single dosage …